Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Davey50, what makes you say Harwood have 15m-20m to sell down? Have they indicated that's their intention or is that your opinion?
CEO statement: "It has been disappointing that we have not seen the recovery in Regulated Industries as quickly as we would have hoped and that sales in some parts of our content management software business have been slower than planned. We expect both to show some recovery in the second half.
Delivery of the Board's full year expectations remains dependent on continuing to successfully leverage our growth initiatives and AI offerings to compensate for ongoing headwinds in some areas."
Laying the ground for tough times?
The same David1951c. I need to see financing in place and evidence of sales so as to reveal a clear path to sustainability on a cash basis, before investing. Until then, dicey. Plus the market cap is so small now (
On 1st glance update seems ok, until, buried deep inside, one reads that while case volumes are up, size has reduced from £139k to £96k per case. Typical MANO disingenuity! Let's see what the market thinks.
Two obvious questions: (1) were the results encouraging at all for Asos shareholders? (this morning's share price rise has almost disappeared, having been sold into) and (2) is there a read across for Boohoo? (share price here says not really).
Any views?
I see SCE has been around a while - it's not a 3-year wonder like Saietta was - but I don't think it has ever made a profit in all of that time. Are we talking about a zombie company here? One unable to survive without regular infusions of cash? Well, in this macro climate the party's over. Today's share price reaction says the market has totally lost trust in management's ability to deliver. Not a good vibe. I'm starting to doubt management can turn it around.
Down 40% in a week on no news. That's half the profits I made on this company earlier in the year wiped out already. What fun it is to invest in pre-profitable biotechs these days.....
Gotta say, the indiscriminate trashing of share prices on AIM is a heck of a worry. For all of these companies, why bother paying a subscription to be on a public market if no-one wants your shares and you can't raise finance except at silly prices, while there's a wall of money looking for interesting companies waiting in the wings in the private sphere?
Not good.
(Note to self: don't touch sub £200m, regardless of the story, until things change).